Cranberry for the Prevention of Urinary Tract Infections
Primary Purpose
Urinary Tract Infection
Status
Unknown status
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Cranberry concentrate
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Urinary Tract Infection
Eligibility Criteria
Inclusion Criteria:
- Females who have had at least 2 clinical-diagnosed symptomatic UTIs in the year preceding
- Can communicate in English
Exclusion Criteria:
- Current UTI
- Pregnant or breastfeeding or planning a pregnancy in the next 12 months
- known allergy or intolerance to cranberry-containing products
- A history of renal stones and/or renal transplantation
- Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes
- Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement
- Intermittent or indwelling catheterization
- Any anatomic abnormalities of the urinary tract
- The use of any antibiotics within 2 weeks before study entry
- The use of any natural health products, including herbs, homeopathic products, or other forms of cranberry supplements within 2 weeks before study entry
Sites / Locations
- The University of British ColumbiaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Cranberry concentrate
Placebo
Arm Description
Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
A capsule containing control formulation
Outcomes
Primary Outcome Measures
Number of urinary tract infections
Secondary Outcome Measures
Full Information
NCT ID
NCT02454309
First Posted
May 22, 2015
Last Updated
May 30, 2016
Sponsor
University of British Columbia
1. Study Identification
Unique Protocol Identification Number
NCT02454309
Brief Title
Cranberry for the Prevention of Urinary Tract Infections
Official Title
A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
March 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of British Columbia
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study aims to determine whether a cranberry concentrate reduces recurrent urinary tract infections (UTIs) in women. Approximately 150 adult women will be recruited to participate in this study. Subjects will be randomized to either the cranberry supplement or placebo treatment for 12 months. Subjects and investigators will be blinded to which supplement they are taking.
Detailed Description
Participants will be randomized to receive either a cranberry concentrate or placebo. Participants, study staff and investigators will remain blinded until after the dataset has been cleaned. At the baseline visit participants will be instructed to consume the assigned supplement twice daily for 12 consecutive months. A calendar will be provided to record compliance, recurrent UTIs and any side effects. Participants will be phoned/texted each month to encourage participation. Additional study visits will be completed at 3 months, 6 months and 9 months to collect information on recurrent UTIs and adherence. A urine sample will be collected from participants at each visit to test for pregnancy and the presence of an undetected UTI. Supplements will be distributed at each visit for the following 3-month study period and the last bottle of unused product returned. At the 12-month visit, participants will complete an end-line questionnaire and return their supplement bottle in addition to the calendar and side effect diary. If participants withdraw from the study, they will be encouraged to return at 12 months to complete a survey to allow for intent-to-treat analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infection
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cranberry concentrate
Arm Type
Experimental
Arm Description
Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A capsule containing control formulation
Intervention Type
Dietary Supplement
Intervention Name(s)
Cranberry concentrate
Other Intervention Name(s)
Cranrich (™)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Number of urinary tract infections
Time Frame
12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Females who have had at least 2 clinical-diagnosed symptomatic UTIs in the year preceding
Can communicate in English
Exclusion Criteria:
Current UTI
Pregnant or breastfeeding or planning a pregnancy in the next 12 months
known allergy or intolerance to cranberry-containing products
A history of renal stones and/or renal transplantation
Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes
Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement
Intermittent or indwelling catheterization
Any anatomic abnormalities of the urinary tract
The use of any antibiotics within 2 weeks before study entry
The use of any natural health products, including herbs, homeopathic products, or other forms of cranberry supplements within 2 weeks before study entry
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah J Harvey, MSc
Phone
6047542245
Email
sarah.harvey@ubc.ca
Facility Information:
Facility Name
The University of British Columbia
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6T 1Z4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tim Green, PhD
12. IPD Sharing Statement
Learn more about this trial
Cranberry for the Prevention of Urinary Tract Infections
We'll reach out to this number within 24 hrs